[Effect of FCE 20,700, an effective oral prostaglandin E2 analog on the human gastric mucosa epithelium].
In randomised double-blind crossover studies the effect of FCE 20700, an oral effective PG E2-analogue, has been evaluated on human gastric secretion, on the behaviour of transmucosal gastric potential difference against acetylsalicylic acid as well as on indomethacin-evoked mucosal lesions of stomach and duodenum in healthy volunteers. Single doses of 500 micrograms and 1500 micrograms FCE 20700 inhibited basal acid output without affecting pentagastrin maximally stimulated acid secretion. Both doses of this prostaglandin analogue prevented completely the drop in gastric potential difference brought about by 1000 mg acetylsalicylic acid. Concomitant administration of 250 micrograms t.i.d. and 750 micrograms t.i.d. FCE 20700 did not reduce the lesion score induced by 50 mg t.i.d. indomethacin over 6 days.
D000284:Administration, Oral; D000328:Adult; D001241:Aspirin / Q000494:pharmacology; D015232:Dinoprostone / Q000031:analogs & derivatives*; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004848:Epithelium / Q000187:drug effects; D005744:Gastric Acid / Q000378:metabolism; D005753:Gastric Mucosa / Q000187:drug effects*; D005773:Gastroscopy; D006801:Humans; D007213:Indomethacin / Q000494:pharmacology; D008297:Male; D008564:Membrane Potentials / Q000187:drug effects; D010418:Pentagastrin; D011459:Prostaglandins E, Synthetic / Q000494:pharmacology*; D011897:Random Allocation
D011459:Prostaglandins E, Synthetic; C040808:FCE 20700; D010418:Pentagastrin; D015232:Dinoprostone; D001241:Aspirin; D007213:Indomethacin
Effekte von FCE 20700, einem oral wirksamen Prostaglandin-E2-Analogon, auf das menschliche Magenschleimhautepithel.